Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 288,266 | 453,932 | 112,546 | 144,454 | 383,928 |
| Receivables | 473,575 | 457,445 | 400,619 | 368,348 | 331,429 |
| Inventories | 381,877 | 380,282 | 367,823 | 269,030 | 209,873 |
| Other current assets | 256,179 | 203,595 | 220,489 | 173,823 | 137,508 |
| TOTAL | $1,399,897 | $1,495,254 | $1,101,477 | $955,655 | $1,062,738 |
| Non-Current Assets | |||||
| PPE Net | 713,123 | 702,177 | 649,474 | 587,667 | 555,167 |
| Intangibles | 516,776 | 450,461 | 459,467 | 458,380 | 52,543 |
| Other Non-Current Assets | 663,647 | 612,033 | 536,347 | 435,501 | 624,113 |
| TOTAL | $1,893,546 | $1,764,671 | $1,645,288 | $1,481,548 | $1,231,823 |
| Total Assets | $3,293,443 | $3,259,925 | $2,746,765 | $2,437,203 | $2,294,561 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 167,787 | 74,997 | 74,982 | 74,996 | 49,988 |
| Accounts payable and accrued liabilities | 114,211 | 110,643 | 110,221 | 116,140 | 74,558 |
| Accrued Expenses | 502,119 | 478,712 | 433,662 | 458,909 | 415,648 |
| TOTAL | $1,067,916 | $951,547 | $1,235,803 | $763,579 | $582,761 |
| Non-Current Liabilities | |||||
| Long Term Debt | 449,786 | 622,883 | 694,387 | 775,205 | 858,492 |
| Deferred Revenues | 33,799 | 37,195 | 37,938 | 40,034 | 42,567 |
| Other Non-Current Liabilities | 142,177 | 165,197 | 168,826 | 158,319 | 162,288 |
| TOTAL | $630,214 | $823,848 | $902,225 | $983,632 | $1,079,005 |
| Total Liabilities | $1,698,130 | $1,775,395 | $2,138,028 | $1,747,211 | $1,661,766 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 81,328 | 83,089 | 82,903 | 84,249 | 85,426 |
| Common Shares | 10,784 | 10,751 | 10,719 | 10,688 | 10,646 |
| Retained earnings | 5,332,438 | 4,444,571 | 3,599,529 | 2,920,440 | 2,175,595 |
| Other shareholders' equity | -87,772 | -65,357 | -72,726 | -47,456 | -48,295 |
| TOTAL | $1,595,313 | $1,484,530 | $608,737 | $689,992 | $632,795 |
| Total Liabilities And Equity | $3,293,443 | $3,259,925 | $2,746,765 | $2,437,203 | $2,294,561 |